JP2009532415A - Pi3−キナーゼインヒビターとして使うためのチアゾリルジヒドロシクロペンタピラゾール - Google Patents

Pi3−キナーゼインヒビターとして使うためのチアゾリルジヒドロシクロペンタピラゾール Download PDF

Info

Publication number
JP2009532415A
JP2009532415A JP2009503534A JP2009503534A JP2009532415A JP 2009532415 A JP2009532415 A JP 2009532415A JP 2009503534 A JP2009503534 A JP 2009503534A JP 2009503534 A JP2009503534 A JP 2009503534A JP 2009532415 A JP2009532415 A JP 2009532415A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
aryl
phenyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532415A5 (cg-RX-API-DMAC7.html
Inventor
シュテフェン ブライトフェルダー
ウド マイアー
クリシュトフ ヘンケ
アンネ テー イェルゲンセン
アレクサンダー パウチュ
トリクシー ブラントル
マティアス グラウエルト
マティアス ホフマン
シュテファン ショイエラー
クラウス エルブ
ミハエル ピーペル
インゴ プラクシュト
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2009532415A publication Critical patent/JP2009532415A/ja
Publication of JP2009532415A5 publication Critical patent/JP2009532415A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2009503534A 2006-04-06 2007-03-27 Pi3−キナーゼインヒビターとして使うためのチアゾリルジヒドロシクロペンタピラゾール Pending JP2009532415A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06112298 2006-04-06
PCT/EP2007/052914 WO2007115931A1 (de) 2006-04-06 2007-03-27 Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren

Publications (2)

Publication Number Publication Date
JP2009532415A true JP2009532415A (ja) 2009-09-10
JP2009532415A5 JP2009532415A5 (cg-RX-API-DMAC7.html) 2010-05-13

Family

ID=36764026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503534A Pending JP2009532415A (ja) 2006-04-06 2007-03-27 Pi3−キナーゼインヒビターとして使うためのチアゾリルジヒドロシクロペンタピラゾール

Country Status (15)

Country Link
US (1) US7517995B2 (cg-RX-API-DMAC7.html)
EP (1) EP2007382A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009532415A (cg-RX-API-DMAC7.html)
KR (1) KR20080111118A (cg-RX-API-DMAC7.html)
CN (1) CN101460167A (cg-RX-API-DMAC7.html)
AR (1) AR060267A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007236045A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710306A2 (cg-RX-API-DMAC7.html)
CA (1) CA2647292A1 (cg-RX-API-DMAC7.html)
IL (1) IL194494A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008012534A (cg-RX-API-DMAC7.html)
RU (1) RU2008143547A (cg-RX-API-DMAC7.html)
TW (1) TW200806679A (cg-RX-API-DMAC7.html)
WO (1) WO2007115931A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200807713B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012133509A1 (ja) * 2011-03-29 2012-10-04 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体
JP2015516976A (ja) * 2012-04-17 2015-06-18 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス処置のための化合物および方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004016179A1 (de) * 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
CA2738868C (en) 2008-10-01 2017-01-17 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
JP5579724B2 (ja) * 2008-10-17 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ホスファチジルイノシトール−3−キナーゼ(pi−3キナーゼ)阻害剤としてのテトラ−アザ−複素環
WO2010125799A1 (ja) 2009-04-27 2010-11-04 塩野義製薬株式会社 Pi3k阻害活性を有するウレア誘導体
EA201200087A1 (ru) 2009-07-02 2012-07-30 Новартис Аг 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k
US20140213630A1 (en) * 2011-03-08 2014-07-31 Thomas Diacovo Methods and pharmaceutical compositions for treating lymphoid malignancy
JP2022515256A (ja) 2018-12-25 2022-02-17 ソル - ゲル テクノロジーズ リミテッド Egfr阻害剤を含む組成物による皮膚障害の治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515852A (ja) * 2004-10-07 2008-05-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pi3キナーゼ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL357099A1 (en) 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AR038703A1 (es) 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
MXPA05000453A (es) 2002-07-10 2005-03-23 Applied Research Systems Derivados de benceno fusionados a azolidinona-vinilo.
WO2004029055A1 (en) 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
CA2504335A1 (en) 2002-10-30 2004-05-13 Toppan Printing Co., Ltd. Apparatus of wiring pattern, inspection method, detection apparatus, detection method
BR0316386A (pt) 2002-12-06 2005-09-27 Warner Lambert Co Benzoxazin-3-onas e seus derivados como inibidores de p13k
WO2004056820A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
CA2528938A1 (en) 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
GB0315966D0 (en) 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515852A (ja) * 2004-10-07 2008-05-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pi3キナーゼ

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012133509A1 (ja) * 2011-03-29 2012-10-04 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体
JP2015516976A (ja) * 2012-04-17 2015-06-18 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス処置のための化合物および方法
JP2017128596A (ja) * 2012-04-17 2017-07-27 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス処置のための化合物および方法

Also Published As

Publication number Publication date
US7517995B2 (en) 2009-04-14
AU2007236045A1 (en) 2007-10-18
EP2007382A1 (de) 2008-12-31
RU2008143547A (ru) 2010-05-20
AR060267A1 (es) 2008-06-04
MX2008012534A (es) 2008-10-10
TW200806679A (en) 2008-02-01
BRPI0710306A2 (pt) 2011-08-09
KR20080111118A (ko) 2008-12-22
US20070238730A1 (en) 2007-10-11
IL194494A0 (en) 2009-08-03
WO2007115931A8 (de) 2008-06-12
CN101460167A (zh) 2009-06-17
ZA200807713B (en) 2009-08-26
CA2647292A1 (en) 2007-10-18
WO2007115931A1 (de) 2007-10-18

Similar Documents

Publication Publication Date Title
JP5237262B2 (ja) チアゾリル−ジヒドロキナゾリン
KR20080111118A (ko) Pi3-키나제 억제제로서 사용하기 위한 티아졸릴디하이드로사이클로펜타피라졸
JP2009532417A (ja) チアゾリルジヒドロインダゾール
KR20090006181A (ko) 티아졸릴디하이드로인다졸
KR20070064660A (ko) Pi3 키나제
JP2011529931A (ja) 4−ジメチルアミノ−フェニルで置換されているナフチリジン、及び医薬としてのその使用
JP5303450B2 (ja) チアゾリル−ジヒドロキナゾリン
NZ563448A (en) Benzofuranone derivatives for treating inflammatory diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20121105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130430